<DOC>
	<DOCNO>NCT01200420</DOCNO>
	<brief_summary>The main purpose study determine safety tolerability multiple dose miravirsen subject infect chronic hepatitis C. Secondary purpose include assessment pharmacokinetics miravirsen assessment miravirsen 's effect HCV viral titer .</brief_summary>
	<brief_title>Multiple Ascending Dose Study Miravirsen Treatment-Naïve Chronic Hepatitis C Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>BMI 1838 kg/m2 Treatmentnaïve interferonalpha base therapy HCV genotype 1 Clinical laboratory finding consistent clinical diagnosis CHC , include : Previous documentation positive HCV serology ( HCV antibody HCV RNA ) least 24 week prior enrollment , OR Positive HCV serology ( HCV antibody HCV RNA ) prior remote risk factor ( 24 week prior Screening ) acquisition hepatitis C Serum HCV RNA &gt; 75,000 IU/mL Screening ( North American site ) . Liver biopsy within 36 month Day 1 , indicate absence cirrhosis Screening hematology , clinical chemistry , coagulation urinalysis clinically significant follow criterion meet : Platelets &gt; 100,000/mm3 Total WBC &gt; 3000/mm3 ANC &gt; 1500/mm3 Hemoglobin &gt; 11 g/dL female &gt; 12 g/dL male Total direct bilirubin , WNL ( except clearly document Gilbert 's Syndrome ) ALT &lt; 5 x ULN Serum creatinine WNL creatinine clearance calculate CockcroftGault formula &gt; 80 ml/min Negative result follow Screening laboratory test : urine serum pregnancy test ( woman childbearing potential ) , hepatitis B surface antigen human immunodeficiency virus ( HIV ) antibody . For men woman childbearing potential , willingness utilize adequate contraception become pregnant ( partner become pregnant ) full course study . Adequate contraceptive measure include oral contraceptive ( stable use 2 cycle prior Screening ) . IUD , DepoProvera , Norplant System implant , bilateral tubal ligation , vasectomy , condom diaphragm plus either contraceptive sponge , foam jelly abstinence . Other know cause liver disease except CHC History symptom decompensated liver disease : ChildPugh Class B C , include ascites , hepatic encephalopathy , esophageal variceal bleeding , fibrosis sign hepatic insufficiency portal hypertension History hepatocellular carcinoma ( HCC ) image study serum alphafetoprotein ( AFP ) &gt; 50 ng/mL Screening Concurrent clinically significant medical diagnosis ( hepatitis Crelated condition ) would potentially interfere subject study compliance confound study result Concurrent social condition ( e.g . drug , alcohol , transportation ) would potentially interfere subject 's study compliance Clinically significant illness within 30 day precede entry study Participated investigational drug study within 30 day 5 halflives , whichever longer , prior start study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Antisense</keyword>
	<keyword>miR-122 antagonist</keyword>
	<keyword>host factor</keyword>
	<keyword>CHC</keyword>
</DOC>